STAT+: Pharmalittle: We’re reading about a Novo setback, support for Replimune’s melanoma drug, and more

<iframe
  src="https://statesidedaily.com/embed/cluster/a38bca77a9cabead55da395f36da339dd30416bc"
  width="100%" height="320"
  style="border:0;max-width:680px"
  loading="lazy"
  title="STAT+: Pharmalittle: We&#8217;re reading about a Novo setback, support for Replimune&#8217;s melanoma drug, and more"></iframe>